Skip to main content

Table 3 Symptom severity, duration and medication use from diary

From: Pelargonium sidoides root extract for the treatment of acute cough due to lower respiratory tract infection in adults: a feasibility double-blind, placebo-controlled randomised trial

 

Liquid Kaloba® (n = 31)

Liquid placebo (n = 26)

Tablet Kaloba® (n = 21)

Tablet placebo (n = 22)

All participants

Last day of any moderately bad symptoms1

7 (4,15)

12 (4,17)

9 (5,13)

9 (4,15)

9 (4,14)

First day of no moderately bad symptoms2

7 (4,8)

8 (4,13)

6.5 (4,11)

8 (5,14.5)

7 (4,11)

Last day of any symptoms

9 (6,17)

13.5 (7,19)

11 (8,14)

12.5 (8,24)

11 (7,17.5)

First day of no symptoms

10 (6,12)

12 (6,17)

7 (6,12)

11 (8,15)

9 (6,14)

Moderately bad symptoms resolved by day 7?

17/31 (54.8%)

9/26 (34.6%)

9/21 (42.9%)

10/22 (45.5%)

45/97 (46.4%)

Moderately bad symptoms resolved by day 14?

23/31 (74.2%)

17/26 (65.4%)

18/21 (85.7%)

16/22 (72.7%)

74/100 (74.0%)

All symptoms resolved by day 7?

10/31 (32.3%)

7/26 (26.9%)

4/21 (19.1%)

5/22 (22.7%)

26/100 (26.0%)

All symptoms resolved by day 14?

22/31 (71.0%)

15/26 (57.7%)

16/21 (76.2%)

14/22 (63.6%)

67/100 (67.0%)

Antibiotics started?

15/31 (48.4%)

6/26 (23.1%)

9/21 (47.6%)

11/22 (50.0%)

41/100 (41.0%)

Days to first dose of antibiotics in those who reported taking them (median, interquartile range)

1 (1,1)

1 (1,8)

1 (1,9)

1 (1,6)

1 (1,4)

  1. 1. The last day of moderately bad symptoms, defined as a score of 3 or more, based on all symptoms recorded in the patient diary
  2. 2. The first day without any moderately bad symptoms, a score of 3 or more, based on all symptoms recorded in the patient diary. As severity of symptoms fluctuates, patients may subsequently experience further days with moderately bad symptoms